Support Centre
25 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
BOrderline personality disorder Study of COgnitive Therapy trial
DOI 10.1186/ISRCTN86177428
ClinicalTrials.gov identifier NCT00538135
EudraCT number
Public title BOrderline personality disorder Study of COgnitive Therapy trial
Scientific title A randomised controlled trial of cognitive therapy plus treatment as usual versus treatment as usual in the treatment of borderline personality disorder
Acronym BOSCOT
Serial number at source 064027; 01/27
Study hypothesis We anticipate that the addition of cognitive behavioural therapy to treatment as usual (CBT plus TAU) in participants with borderline personality disorder will decrease the number of participants with in-patient psychiatric hospitalisations or accident and emergency room contact or suicidal acts over twelve months treatment and twelve months follow-up, compared with treatment as usual (TAU). We also anticipate that CBT plus TAU will lead to superior improvement in quality of life, social, cognitive and mental health functioning compared to TAU alone.
Lay summary Not provided at time of registration
Ethics approval Research Ethics Committee of Greater Glasgow Primary Care NHS Trust gave approval on the 15th August 2001
Study design Multicentre, randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Borderline personality disorder
Participants - inclusion criteria 1. Aged between 18 and 65, either sex
2. Met criteria for at least five items of the borderline personality disorder using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) Axis II Personality Disorders (SCID -II)
3. Had received either in-patient psychiatric services or an assessment at Accident and Emergency services or an episode of deliberate self-harm (either suicidal act or self-mutilation) in the previous 12 months
4. Able to give informed consent
Participants - exclusion criteria 1. Currently receiving in-patient treatment for a mental state disorder
2. Currently receiving a systematic psychological therapy or specialist service, particularly psychodynamic psychotherapy
3. Insufficient knowledge of English to enable them to be assessed adequately and to understand the treatment approach
4. Temporarily resident in the area
5. The existence of an organic illness, mental impairment, alcohol or drug dependence, schizophrenia or bipolar affective disorder, as assessed by SCID I, /P (W/Psychotic Screen) (version two)
Anticipated start date 01/02/2002
Anticipated end date 01/10/2004
Status of trial Completed
Patient information material
Target number of participants 106
Interventions Those participants who met the inclusion criteria and who agreed to give written informed consent to take part in the study then completed baseline assessments and were randomly allocated to either one of two active treatment groups namely, TAU, or CBT plus TAU.

CBT is a structured, time limited, psycho-social intervention which has been developed to treat those with Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework.

Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Up to 30 sessions (minimum 15) of treatment, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place.

Treatment as usual:
All participants received the standard treatment (TAU) they would have received if the trial had not been in place. It was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial.
Primary outcome measure(s) Acts of deliberate self-harm in the twelve months prior to baseline, and the twelve months following baseline. Trial participants are being assessed on all measures at six monthly intervals.
Secondary outcome measure(s) 1. Brief Symptom Inventory
2. Beck Depression Inventory-II
3. State-Trait Anxiety Inventory
4. Social Functioning Questionnaire
5. Inventory of Interpersonal Problems
6. Schema Questionnaire
7. The Euro-Qol quality of life questionnaire
8. Client Service Receipt Inventory (CSRI)

Trial participants are being assessed on all measures at six monthly intervals, except for the Schema Questionnaire and the Brief Symptom Inventory, where both are assessed at end of treatment and end of follow-up only.
Sources of funding The Wellcome Trust (UK) (grant ref: 064027)
Trial website
Publications 1. Protocol in http://www.ncbi.nlm.nih.gov/pubmed/17032157
2. 2006 effectiveness results in http://www.ncbi.nlm.nih.gov/pubmed/17032158
3. 2006 cost-effectiveness results in http://www.ncbi.nlm.nih.gov/pubmed/17032159
4. 2010 six year follow up results in http://www.ncbi.nlm.nih.gov/pubmed/21119151
Contact name Prof  Kate  Davidson
  Address Glasgow Institute of Psychosocial Interventions
Psychological Medicine
Gartnavel Royal Hospital
1055 Great Western Road
  City/town Glasgow
  Zip/Postcode G12 0XH
  Country United Kingdom
  Tel +44 (0)141 211 3900
  Fax +44 (0)141 357 4899
  Email k.davidson@clinmed.gla.ac.uk
Sponsor University of Glasgow (UK)
  Address Research & Enterprise
10 The Square
  City/town Glasgow
  Zip/Postcode G12 8QQ
  Country United Kingdom
  Tel +44 (0)141 330 5005
  Fax +44 (0)141 330 3218
  Email R-E@gla.ac.uk
  Sponsor website: http://www.gla.ac.uk/
Date applied 22/07/2005
Last edited 26/11/2012
Date ISRCTN assigned 22/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.